Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy by Preissner, S.C. et al.
Polymorphic Cytochrome P450 Enzymes (CYPs) and
Their Role in Personalized Therapy
Sarah C. Preissner1☯, Michael F. Hoffmann1☯, Robert Preissner1, Mathias Dunkel1, Andreas Gewiess2,
Saskia Preissner1,3*
1 Charité Universitätsmedizin Berlin, ECRC - Structural Bioinformatics Group, Deutsches Konsortium für Translationale Krebsforschung (DKTK), Berlin,
Germany, 2 Institute for Laboratory Medicine, Berlin, Germany, 3 Charité Universitätsmedizin Berlin, Dental, Oral and Maxillary Medicine, CC3, Berlin, Germany
Abstract
The cytochrome P450 (CYP) enzymes are major players in drug metabolism. More than 2,000 mutations have been
described, and certain single nucleotide polymorphisms (SNPs) have been shown to have a large impact on CYP
activity. Therefore, CYPs play an important role in inter-individual drug response and their genetic variability should
be factored into personalized medicine. To identify the most relevant polymorphisms in human CYPs, a text mining
approach was used. We investigated their frequencies in different ethnic groups, the number of drugs that are
metabolized by each CYP, the impact of CYP SNPs, as well as CYP expression patterns in different tissues. The
most important polymorphic CYPs were found to be 1A2, 2D6, 2C9 and 2C19. Thirty-four common allele variants in
Caucasians led to altered enzyme activity. To compare the relevant Caucasian SNPs with those of other ethnicities a
search in 1,000 individual genomes was undertaken. We found 199 non-synonymous SNPs with frequencies over
one percent in the 1,000 genomes, many of them not described so far. With knowledge of frequent mutations and
their impact on CYP activities, it may be possible to predict patient response to certain drugs, as well as adverse side
effects. With improved availability of genotyping, our data may provide a resource for an understanding of the effects
of specific SNPs in CYPs, enabling the selection of a more personalized treatment regimen.
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Introduction
Inter-individual variability of drug response and drug
clearance is a complex and common problem in clinical
practice [1]. Overlapping substrate specificity of enzymes, a
multitude of single nucleotide polymorphisms (SNPs) [2] and
variations between ethnic groups [3] make prediction of
phenotypic drug response difficult. To avoid treatment failure
and unnecessary toxicity, tailoring dosages and drug-cocktails
for each individual is essential [4].
Differences in drug response can be attributed to variability
in DNA sequences of specific genes which’s products are
crucial for drug metabolism. For instance, SNPs in phase 1
enzymes, such as cytochrome P450 oxidases (CYPs) [3],
phase 2 enzymes, such as Uridine 5'-diphospho-
glucuronosyltransferase (UGTs) [5], and absorptive and efflux
transporters, such as ATP-binding cassette transporters (ABC-
transporters) [4], have been previously reported.
Characterization of these enzymes and the effects of minor
allele variants on the metabolism of specific drugs have been
described in the literature and have recently been compiled by
our group into a comprehensive database called SuperCYP [6].
Phase I reactions include oxidation, reduction, hydrolysis and
cyclization. Using oxygen and NADPH as a co-substrate, CYPs
are the major enzymes responsible for catalyzing such
reactions [7] and account for approximately 75% of total drug
metabolism [8].
The Human Genome Project identified 57 human CYPs,
which were classified into 18 families and 43 subfamilies based
on sequence similarity [9]. CYP families 1, 2 and 3 are
responsible for metabolism of drugs, xenobiotics and certain
endogenous molecules [3] and hence are of particular
relevance to this current study. Most CYPs metabolize more
than one drug. Similarly, a drug is often metabolized by
multiple CYPs. Drugs can also inhibit or induce CYP activity,
either by directly interacting with the enzyme or altering its
PLOS ONE | www.plosone.org 1 December 2013 | Volume 8 | Issue 12 | e82562
expression. Characterization of these interactions is important
to determine and predict compatible drug combinations [10].
Human CYPs are primarily membrane-associated proteins [11]
that are ubiquitously expressed in most tissues. Highest
expressions are generally found in liver tissue, but the
distribution of particular CYPs varies [12], which indicates that
the actual efficiency of a drug is likely to depend on CYP
expression in the target tissue. There are significant inter-
individual differences in enzyme activity leading to distinct
phenotypes. For example the most frequent phenotype of CYP
2D6 is the extensive-metabolizer (78.8%), followed by
intermediate- (12.1%), poor (7.6%) and ultra-rapid metabolizers
(1.5%) [13].
In addition to drug catabolism, many CYPs are responsible
for activation of prodrugs, such as cancer therapeutics [14] and
antipsychotics [15]. Prodrugs are pharmacologically inactive
compounds that require activation via metabolic conversion
[16], allowing control of where, when and how much drug
activity occurs [17]. This is particularly important for
chemotherapeutic drugs, where the active drug ideally only
acts on tumor cells in order to reduce toxic side effects [18].
Prodrugs can be activated by photo irradiation [19], change in
pH [20] or enzymatically [21], for instance by CYPs [22].
Polymorphisms in CYPs can result in ineffective or aberrant
activation of prodrugs [22], which can lead to toxicity [4].
Fortunately, advances in genetic research have made
genotyping of a large number of patients possible, leading to
identification of SNPs that alter expression or activity of drug
metabolizing enzymes [3]. In this study we set out to determine
the most frequent CYP polymorphisms having the highest
impact on drug metabolism in Caucasians. This knowledge
could facilitate the development of tests for efficient genotyping
of patients thus leading to a better and more personalized
treatment.
Methods
Text mining
Information on drug metabolism can be found in more than
100,000 PubMed articles, yet limited data is available regarding
the frequencies of SNPs in human CYPs. To identify relevant
articles, a specific search tool was developed for text mining
literature using Apache Lucene™ (http://lucenenet.apache.org)
as a search engine library and LingPipe (http://alias-i.com/
lingpipe). Figure 1 summarizes the different methods used for
the textmining approach. Complete Medline/PubMed data were
downloaded from the NCBI FTP site in xml-format and then
indexed. The indexed data was dynamically queried by a
search engine written in Java that outputs an sql‑file with the
text mining hits, which served afterwards for manual validation.
The search engine comprises several lists of synonyms for
identifying entities, such as chemical compounds, biological
targets, genes, cell types and polymorphisms, as well as
interaction-related entities. If available, information on CYP
polymorphism was extracted from the literature. Definitions and
synonyms are included from UMLS® Metathesaurus®, that
contains millions of biomedical and health related concepts,
their synonymous names, and their relationships. As an
example, the query for CYP2C19 was like:
(Abstract: CYP2C19\** OR Title: CYP2C19\**) AND
(Abstract: population OR Title: population) AND (Abstract:
effect OR Title: effect) AND (Abstract: frequenc* OR Title:
frequenc*).
The term ‘CYP2C19’ was replaced through each human
CYP and synonyms, as well as different ethnicity and outcome
terms were used for ‘population’ and ‘effect’. The positional
distance between the different terms had to be restricted to
reduce false positive hits, when terms occurred far from each
other in the abstract. The records found were scored rule-
based. The rules employed order, redundancy, distance, topic
segmentation and sentence breaking for boundaries. For
example, a distance ≦ 7 between the CYP and the ethnicity
and ≦ 6 between the frequency and the CYP was given a
score of 100. Greater distances and negative interaction words
resulted in lower scores. Duplicates were removed and a team
of scientists manually processed 1,037 papers found in
PubMed for relevance to polymorphisms and their frequency in
Caucasian populations. The team consisted of three medical
scientists, with three years experience in validation of text
mining results. During this time, they reviewed over 10,000
abstracts with the focus on CYPs. A weekly meeting took place
to ensure and raise the quality of text mining and to discuss
problems. The aim was to achieve a coherent review operation.
The text mining validation tool is shown in Figure 2. CYP
polymorphisms that occurred with a frequency of more than
one percent in the Caucasian population were included in this
study.
Localization of SNPs in a 3D CYP model
The evolutionary conservation taken from a multiple
sequence alignment of CYPs was projected onto the 3D
structure using CYP 2D6 as template (PDB ID: 3TDA).
Frequent SNPs in the four most polymorphic CYPs (1A2, 2C9,
2C19 and 2D6) were labeled in the 3D model. The number of
mutations was used to determine the thickness of the ribbon
(Figure 3).
CYP SNPs and 1,000 Genomes
The 1,000 Genomes Project (www.1000genomes.org) is an
international initiative designed to provide full genomic
sequence information from an ethnically diverse population
[23]. CYP SNPs in 1,092 individuals were extracted using the
online data slicer from the 1,000 Genomes Project (http://
browser.1000genomes.org). Frequency analysis focused on
non-synonymous coding SNPs with a prevalence of one
percent or higher in all genomes regardless of ethnicity. The
search included the main 29 CYP alleles from “The Human
Cytochrome P450 (CYP) Allele Nomenclature Database”
(http://www.cypalleles.ki.se/) [24]. In addition, 16 CYP alleles
not listed in the CYP allele database due to very
heterogeneous distributions were included. The 1,000
Genomes Database includes SNP effect predictions on CYPs,
calculated by PolyPhen [25], which predicts possible functional
alterations in human proteins after amino acid substitution
based on physical and comparative considerations [26].
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Expression data
Affymetrix data was used to compare human CYP mRNA
expression in 41 different types of tissue, further
subcategorized into different regions of an organ, yielding a
total of 65 tissue types. The series of datasets obtained from
GEO (Gene Expression Omnibus, http://www.ncbi.nlm.nih.gov/
geo/) were originally generated from 10 post-mortem donors (5
females and 5 males), and represent normal human tissues
(Series GSE3526) [27]. The 84 probe sets, which measure the
expression level of CYPs were normalized and assigned to 40
types of CYPs. To display differences in expression, a heat-
map was generated using Genesis software [28]. Relative
expression was calculated as the intensity of the gene in the
region minus the mean intensity of the gene in all regions then
divided by the standard deviation. This heat-map served as
data source for the CYP body map in which only two-fold
decreased or increased values were considered.
Our work would not have been possible without the publicly
available datasets mentioned above. We are grateful and
honor the work of involved research groups.
Results
Frequencies of SNPs in CYPs
Analysis of the SNPs identified by text mining, showed that
SNPs predominantly occurred in 3 polymorphic CYPs (2D6,
2A6 and 2B6) regardless of ethnic group. Only frequencies of
known nucleotide changes were assessed to identify the extent
of SNPs in CYPs. Figure 4 displays 9 CYPs, including 2D6
(114 SNPs), 2A6 (68 SNPs) and 2B6 (57 SNPs), which
showed the highest number of SNPs. For other CYPs, the
number of known SNPs was less than 22. CYP 2D6 is a major
polymorphic CYP and, as expected, was the greatest
contributor of polymorphic alleles in Caucasians.
Figure 1.  Flow-chart of the methods used for the text mining approach.  
doi: 10.1371/journal.pone.0082562.g001
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Allelic frequency in CYPs of Caucasians
The PubMed search yielded articles on 34 different CYP
alleles with an occurrence greater than one percent in the
Caucasian population (Table 1), which may be indicative of
altered substrate metabolism. CYP 2D6 and 2B6 possessed
the largest number of alleles with a known impact on
metabolism in Caucasian population (11 and 6, respectively).
Maximum allele frequencies in CYP 2D6 varied from 20.7% to
32.4%. When considering all 34 alleles, the most frequent
alleles were CYP 3A5*3C at 81.3% (decreased enzyme
activity) followed by CYP 1A2*1F at 33.3% (increased enzyme
activity). Furthermore, the major alleles leading to increased
metabolism were CYP 2A6*1B (30.0%), 3A4*1B (17.0%),
1A1*2A (19.0%) and 2C19*17 (18.0%). In contrast, decreased
metabolism was attributed to 2D6*2A (32.4%), 2D6*4 (20.7%)
and 2C9*2 (16.0%). Carrying the 2A6*4 allele (1.0%) leads to
an inactive enzyme with no detectable substrate metabolism.
Comparison among different ethnic groups revealed that
frequencies differed considerably and displayed a
heterogeneous distribution of CYP alleles. For instance, in
Asian and African populations, CYP2A6*2 possessed a
frequency of 28.0% and 62.0%, respectively, whereas a
frequency of 8.0% was observed in Caucasians. A more
detailed table with additional information on CYP SNPs in
Caucasians and other ethnic groups is available in Table S1.
Major drug metabolizing CYPs
Not all 57 human CYPs are involved in drug metabolism. The
primary CYPs responsible for drug metabolism were
determined by first ranking the CYPs according to the total
number of drug substrates (Figure 5). Twelve CYPs accounted
for 93.0% of drug metabolism, regarding to the entire number
of 1.839 known drug-metabolizing-reactions in the SuperCYP
database. CYP 1A2, 2D6, 2C9 and 2C19 were responsible for
nearly 40.0% of drug metabolism and including CYP 3A4 even
for 60.0%.
Since the described four CYPs are highly polymorphic and
commonly occur in Caucasians, further detailed analyses were
Figure 2.  Text mining validation tool.  The table shows the text mining validation tool with columns for score, PubMedID, relation
sentence and checkboxes for the validation. The SNPs are highlighted in blue, frequencies in green, effects in orange and the
ethnicities in red. ‘Scientist 1’ reads the abstract and, if necessary, has access to full text. Afterwards, the relation has to be
validated as ‘true’, ‘false’ or ‘not sure’. If the relation is ‘true’, the relation is copied into the ‘comment’ field. These relations are
copied into a new sql-file. If ‘Scientist 1’ activates the ‘not sure’ field, the relation has to be validated again by another scientist.
doi: 10.1371/journal.pone.0082562.g002
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restricted to these four CYPs. On the overall CYP system, it is
expected that these four CYPs would have the greatest impact
on inter-individual variability of drug response. Although CYP
2A6 and 2B6 possess various relevant alleles in Caucasians,
they do not cover a large range of drug interactions (51 and 74
substrates, respectively).
All SNPs in the four most polymorphic CYPs (1A2, 2C9,
2C19 and 2D6) influenced enzymatic activity due to localization
in the substrate-binding cavity as shown in Figure 3.
Expression data
Because of high CYP expression levels in some tissues, an
impact of CYP isoforms in particular tissues can be deduced.
The work of Nishimura and colleagues demonstrated
differences in CYP mRNA expression in various human
tissues. For example, CYP 2F1, 4B1, 4F8, 11S, 11A, 11B1,
11B2, 19 and 24 are not expressed in the liver [29]. The current
study confirmed these results and extended the findings, which
are shown in Figure 6. Nishimura analyzed mRNA levels of 30
CYP isoforms in 11 tissue types. Similarly, the current study
investigated the expression of 40 CYP isoforms in 41 tissue
types. The liver was considered separately in the analysis in
order to identify the differences between the other tissues. In
21 different tissues, a heterogeneous distribution of CYPs was
observed. For instance, 39 different CYP isoforms showed
higher mRNA expression in at least one or more tissue types.
Significant differences were observed in the adrenal gland
cortex, which possessed 6-fold higher expression of CYP
11A1, 11B1 and 11B2 (compared to the mean expression).
Interestingly, no other tissue showed high levels of expression
of these three CYPs. Large differential expression compared to
other tissues was also observed in the kidneys, where a 6-fold
increase in CYP 4A22, a 5-fold increase in CYP 8B1 and 4-fold
increases in 4V2, 4F2, 4A11 and 2B6 were noted. In addition,
5-fold higher expression of CYP 2C8 was found in lung, CYP
4F8 in prostate, 4F3 in bone, 2F1 in bronchial tubes and 2C8 in
Figure 4.  Number of known SNPs per CYP.  The pie chart
illustrates the number of known SNPs in different CYPs.
doi: 10.1371/journal.pone.0082562.g004
Figure 3.  3D structure of a cytochrome with heme and a ligand with localization of frequent SNPs.  Frequent SNPs in the
four most polymorphic CYPs (1A2, 2C9, 2C19 and 2D6) were labeled in this 3D model of CYP 2D6 (PDB ID: 3TDA). Therefore, the
ribbon was enlarged in the appropriate positions. The binding-side (transparent, orange colored surface) contains an iron ion and a
porphyrine ring (heme). Frequent mutations of CYPs at the binding-side occurred at the following positions: 67, 89, 107, 117, 118,
120, 125, 132, 151, 201, 227, 261, 325, 377, 382, 386, 410, 454, 456, 469 and 470.
doi: 10.1371/journal.pone.0082562.g003
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stomach. Furthermore, CYP 2C18 showed a high level
distribution restricted to the oral cavity, pharynx and
esophagus. Two-fold lower expression was detected for CYP
2A1 in the esophagus, 2A7 in the prostate, as well as 2C9 and
2D6 in the spleen.
CYP SNPs and 1,000 Genomes
The current study identified 199 non-synonymous coding
SNPs with frequencies greater than one percent (Table S2).
Compared to the “Human Cytochrome P450 Allele
Nomenclature Database” (http://www.cypalleles.ki.se/), we
found several SNPs in 1,000 Genomes not related to alleles
defined and named in the Database. To elucidate the
difference between the ‘The Human Cytochrome P450 Allele
Nomenclature’ and 1000genome data regarding new SNPs, we
examined CYP2A6 exemplary. Table 2 summarizes SNPs
most likely to alter enzyme activity [25]. It displays five SNPs,
which can lead to an altered enzyme activity with frequencies
between 1.4 and 5.1 %. Only I471T (rs5031016) is also
contained in the CYP nomenclature and reflects the
CYP2A6*36 allele. New updates have to be done to map a
comprehensive CYP SNP data source.
With the potential to alter drug metabolism, the 72 listed
SNPs occurred in 24 CYPs. The most frequent SNPs were
CYP 4A11 rs112743 (42.6%; highly expressed in kidney
tissue), CYP 4F11 rs1060463 (49.5%; highly expressed in
bronchus tissue) and CYP 2A7 rs3869579 (46.7%; highly
Table 1. CYP SNP frequencies in Caucasians.
CYP Allele Amino Acid Caucasian (%) Enzyme Activity Test Drug References (PMID)
1A1 *2A I462V 19.0 increase 17β-estradiol 19514967
1A2 *1F none 33.3 higher inducibility Omeprazole 12534642 / 22299824
 *1D none 4.82 decrease Clozapine 12534642 / 20797314
2C9 *2 R144C 19.0% *1/*2 1.6% *2/*21.8 % *2/*3 decrease Warfarin 15284536
 *3 I359L 9.0 decrease Tolbutamide 11678789
2C19 *2 Splicing I331V defect 16.0 decrease Clopidogrel 10460072
 *17 I331V 18.0 increase Omeprazole 21247447
2D6 *3 N166D; 259 Frameshift 2.04 decrease Debrisoquine 9012401
 *4 P34S; L91M; H94R; Splicing defect;S486T 20.7 decrease Dextromethorphan 9012401
 *4D P34S; Splicing defect; S486T 3.4 decrease Bufuralol 11266079
 *4L P34S; Splicing defect; S486T 4.5 decrease Bufuralol 11266079
 *5 CYP2D6 deleted 4.1 no enzyme  9511177
 *6 118Frameshift 1.3 nonfunctional  9511177
 *7 H324P 1.0 decrease Sparteine 9089660
 *9 K281del 2.0 decrease Sparteine 9511177
 *10 P34S; S486T 8.0 decrease Metoprolol 9511177 / 11505219
 *41 R296C; Splicing defect; S486T 8.0 decrease (expression)  15289790
2A6 *12 10 aa substitutions 2.9 decreased (expression)  16041240
 *1B none 32.6 increase Caffeine 22850738
 *2 L160H 2.3 decrease Nicotine 11259354
 *4 CYP2A6 deleted 1.0 no enzyme  11259354
 *9 (TATA box) 7.1 decreased Nicotine 15475735
3A4 *17 F189S 2.0 decrease Testosterone 11714865
 *1B none 17.0 increase (transcription) Tacrolimus 12692107
 *2 S222P 2.7 decrease Nifedipine 10668853
3A5 *3C Splicing defect 81.3 decrease Sirolimus 17162466
 *3k / *10 Splicing defect; F446S 2.0 decrease Nifedipine 12893984
3A7 *2 T409R 8.0 increase Dehydroepiandrosterone 15903124
2B6 *2 R22C 5.3 increase Artemether 21746968 / 12242601
 *5 R487C 14.0 decrease Nirvanol 11470993
 *4 K262R 5.0 increase Bupropion 14515060
 *6 Q172H; K262R 25.2 decrease (expression) Cyclophosphamide 14515060
 *7 Q172H; K262R; R487C 3.0 decrease 7-ethoxy-4-trifluoromethylcoumarin 12242601 / 14551287
 *22 none 3.0 increase (transcription)  15722458
Polymorphisms that are relevant for Caucasians are shown here with CYP, allele, amino acid and frequencies and their effect on enzyme activity. The test drug and the
PubMed ID complete the table. A more detailed table including gene information and frequencies in other ethnic groups can be found in Table S1.
doi: 10.1371/journal.pone.0082562.t001
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expressed in the pituitary gland but low in the prostate gland).
Our study findings show that some CYPs are not only
heterogeneously expressed, but also highly polymorphic.
Discussion
Genetic diversity and polymorphisms
Mutations in a CYP gene can lead to functional alterations,
such as increased or decreased activity. If a mutant allele
occurs at a frequency of at least one percent in a population, it
is referred to as a pharmacogenetic polymorphism. Such
polymorphisms can be discovered at the genotype level and/or
the phenotype level based on altered function of the enzyme
[30].
Individuals in a population can be stratified according to
metabolic ratios of particular CYPs, which have great clinical
relevance. For example, a CYP 2D6 poor metabolizer should
not be administered codeine since the drug would have no
effect. Conversely, a CYP 2D6 ultra-rapid metabolizer would
likely suffer side effects from a normal dosage [31,32]. CYP
2D6 is a highly polymorphic CYP with at least 70 allelic variants
[33] that can be categorized into four phenotypic classes.
Overall CYP 2D6 expression in liver tissue is only
approximately 2%, but hundreds of drugs are metabolized by
this enzyme, including opiates, beta-blockers, anti-arrhythmics,
tricyclic antidepressants, SSRIs, 5-HT3-antagonists and
neuroleptics [34]. About 10% of the Caucasian population have
difficulties in fully metabolizing these drugs [35], leading to
harmful side effects [32,36]. Therefore, personalized
prescriptions will become of great importance [37].
Personalized medicine
Since 2009, the Clinical Pharmacogenetics Implementation
Consortium (CPIC) provides information on how genetic test
results can be used to optimize drug therapy. The guidelines
center on genes or on specific drugs. For some drugs, they
also provide dosing guidelines for clinicians [38].
Figure 5.  Number of drugs metabolized per CYP.  The pie
chart illustrates the number of drugs that can be metabolized
by a specific CYP.
doi: 10.1371/journal.pone.0082562.g005
Psychiatric drugs.  As most psychiatric drugs are
metabolized by highly polymorphic CYP 2D6 and CYP 2C19,
psychiatrists were first to propose the idea of CYP genotyping
[39–41]. Three state hospitals in Kentucky recruited 4,532
psychiatric patients for genotyping of both CYPs with the help
of DNA microarray technology.
Results from the current study were consistent with previous
studies of allele frequency [35], demonstrating the importance
of personalized prescription given that more than one tenth of
patients are not likely to respond to standard treatment and
suffer unwarranted toxicity. In the study performed by de Leon
and colleagues, the dosage was adapted to the guidelines of
Kirchheiner [15] for antipsychotics and antidepressants. The
authors propose a numeric dosage adaptation system that
reflects expression of CYP 2D6 and CYP 2C19.
Cardiovascular drugs.  An important area of focus is stent
implantation and/or inhibition of blood clots after an acute
coronary syndrome (ACS) to prevent ischemic events.
Therefore, antiplatelet agents are administered before and after
percutaneous coronary intervention (PCI) to reduce the risk of
ischemic events. Currently, the gold standard therapy is a
combination of aspirin and clopidogrel [42,43]. Unfortunately,
approximately 29% of people respond poorly to clopidogrel [44]
and, therefore, have an increased risk for recurrent ischemic
events after PCI [45]. Several different factors were discovered
to contribute to the variability in clopidogrel response, including
polymorphisms, impaired absorption or bioavailability, poor
compliance and pre-existing conditions (increased body mass
index, diabetes mellitus, ACS) [46]. In addition, clopidogrel is a
prodrug that requires activation through the CYP system. The
activated metabolite inhibits the ADP P2Y12 receptor [47].
Polymorphisms causing loss of function in the CYP system are
associated with poor drug response. Most notably, the CYP
2C19*2 polymorphism was shown to lead to a 30% increased
risk of major adverse cardiovascular events during treatment
with clopidogrel [48–51]. Furthermore, the CYP 2B6*5 and
P2Y12 polymorphisms are also associated with clopidogrel
resistance [52]. In contrast, an enhanced response due to
increased transcriptional activity occurs with the CYP 2C19*17
polymorphism, leading to increased risk of bleeding during
clopidogrel therapy [53,54].
The CYP3A4*2 allele with a frequency of 2.7 % in Caucasian
leads in vitro to reduced (six fold to nine fold) intrinsic
clearance for nifedipine [55]. This could have a great influence
on the tolerability of patients getting this dihydropyridine
calcium channel blocker. Indications for nifedipine are widely
distributed, e.g. Angina pectoris, Hypertonia, Achalasia and
Raynaud's phenomenon, so the application is very common.
An in vivo research regarding the alteration of nifedipine
metabolism in CYP3A4*2 patients should be done, to possibly
prevent toxic and/or increased side effects.
Previous findings described above, emphasize the
importance of CYP polymorphisms and alternatively
metabolized drugs in clinical practice. Prediction of CYP activity
may be helpful to assess drug response. For instance, the
(13)C-pantoprazole breath test, which measures CYP 2C19
activity, can detect clopidogrel resistance [56] and support use
Polymorphic CYPs in Personalized Therapy
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of suitable drug alternatives like Ticagrelor (no activation
required, metabolized via CYP 3A4).
Additional observed effects
Apart from altered drug metabolism, CYP polymorphisms
were also potentially associated with neoplastic growth,
adverse psychological behavior and other diseases. In women,
polymorphisms in CYP 1A1 seemed to increase susceptibility
to genital cancers [57,58]. Conversely, the CYP 2D6*4
polymorphism has been shown to have a protective effect
against breast cancer [59]. Furthermore, 2C19*2, 2D6*4,
2D6*10 and 1A1*2A have been associated with increased risk
of head and neck squamous cell carcinoma [60].
In addition to the role that CYP polymorphisms play in
pathological processes and susceptibility to certain diseases,
recent genome-wide association studies (GWASs) have
demonstrated an association between increased coffee
consumption and SNPs rs2472297-T (located between
CYP1A1 and CYP1A2) and rs6968865 (next to aryl
hydrocarbon receptor) [61]. Huo et al. (2012) determined that
certain SNPs are associated with increased susceptibility to
schizophrenia [62], while Peñas-Lledó and colleagues found a
positive association between the extent of active CYP 2D6 and
frequency of suicide attempts, providing evidence that CYP
diversity may need to be accounted for in clinical practice [63].
Figure 6.  Body map of cytochrome P450 enzyme expression.  A schematic map of the specific expression of different CYPs in
human organs is presented. Expression values are relative to the mean expression in all organs. At least three-fold higher
expression of a CYP in one organ is indicated by red text. At least three-fold lower expression is indicated by green text. A color
spectrum for the expression values is illustrated in the provided scale. CYPs with average expression in one organ were not
included.
doi: 10.1371/journal.pone.0082562.g006
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Diversity of expression in human tissues
Variable expression of functionally distinct CYP isoforms
across different tissue types indicates that certain isoforms play
specific roles in a tissue-dependent manner. Figure 6 provides
an illustrative overview of CYP expression in the human body.
Such knowledge may be useful for development of new
prodrugs activated by a specific CYP highly expressed in the
preferentially targeted tissue, ultimately leading to increased
bioavailability at the target site and reduced side effects. On
the other hand, variable expression of CYPs in different tissues
may adversely affect drug efficacy in some tissues. Such a
case could occur if drugs undergo an inactivation through a
higher expressed CYP in their target tissues. Regardless,
further clinical investigation is required.
Even polymorphic CYP isoforms show a heterogeneous
tissue distribution. In particular, CYP 1A2, 2C19 and 2D6 are
highly expressed in the pituitary gland. Furthermore, highest
expression of CYP 2C9 was detected in the cerebellum, while
greatest expression of 2D6 and 2B6 were found in skeletal
muscle and kidneys. The influence of mutations in CYPs in
particular organs remains to be determined and requires further
investigation.
Differential distribution of CYPs may have an influence on
specific side effects of drugs. For example, cyclophosphamide
(CPA) therapy can lead to development of hyponatremia. CPA
is a prodrug converted by CYP 2B6 into the active form [64].
Table 2. Differentially expressed CYPs and their SNP frequencies.
CYP ID Mutation Amino Acid Global frequency (%) CYP ID Mutation Amino acid Global frequency (%)
3A43 rs45450092 435G>T M145I 1.5 2F1 rs144315434 1172T>C L391P 5.4
 rs45621431 825G>A M275I 2.3  rs146029724 1330A>C M444L 6.5
 rs680055 1018C>G P340A 13.4 2W1 rs61746347 557G>A R186H 2.8
 rs78548296 389G>A R130Q 1.0  rs117826462 547C>G L183V 1.4
4A11 rs1126743 1374C>G I458M 42.6 4F11 rs1060463 1271G>A R424Q 49.5
 rs4926581 553G>T V185F 28.1  rs148197835 538C>T R180C 4.2
 rs61736429 1525C>T L509F 2.1  rs57519667 436C>T R146C 1.6
 rs62618709 553G>T V185F 1.1 2C18 rs115091705 431G>A R144H 1.7
4A22 rs112604161 181G>A G61R 1.6  rs117111102 370C>T R124W 1.4
 rs113777592 553G>T V185F 29.6  rs2281891 1154C>T T385M 19.3
 rs2056900 388G>A G130S 29.9  rs41286880 1004G>A R335Q 2.5
 rs4926600 1525C>T L509F 12.9  rs79500998 1324C>T R442C 1.0
 rs61507155 311A>T Y104F 6.6 7A1 rs8192875 1039G>A D347N 1.6
 rs61736431 1154C>T P385L 1.2 4F12 rs16995378 47C>T T16M 7.6
4B1 rs12094024 986A>C Y329S 2.2  rs57578760 808G>C V270L 3.7
 rs2297809 1123C>T R375C 18.3  rs76142062 88C>A L30I 3.4
 rs4646487 517C>T R173W 16.8 11B1 rs11775687 562C>T P188S 5.7
 rs59694031 1109G>C C370S 4.0  rs9657020 593C>T T198M 12.7
4F2 rs2074900 515C>T Thr172I 25.4 4F3 rs118159249 1420G>A A474T 1.1
 rs2108622 1297G>A V433M 20.9 2A7 rs111390860 988C>T R330W 1.0
 rs3093153 554G>T G185V 3.7  rs184466431 1301G>T R434L 1.2
 rs3093200 1555C>A L519M 8.4  rs3869579 778C>T R260C 46.7
5A1 rs13306050 1372C>T R458C 3.3  rs60711313 1259T>C I420T 3.2
 rs13306052 679GA V227M 1.4  rs75152309 1106A>T K369M 6.6
 rs6952940 544C>T P182S 2.4  rs78754793 244G>C A82P 2.4
2A6 rs5031017 1436G>T G479V 1.4 2S1 rs34971233 1397C>T P466L 1.1
 rs5031016 1412T>C I471T 5.1 2E1 rs6413419 535G>A V179I 7.2
 rs28399499 983T>C I328T 2.3  rs28969387 1370A>T H457L 6.3
 rs8192709 64C>T R22C 4.5 2C19 rs17884712 431G>A R144H 1.4
 rs28399499 383T>C I128T 2.3 8A1 rs5626 706C>T R236C 3.7
2C8 rs11572103 805A>T I269F 16.4 2D6 rs2982054 986G>A R329H 31.2
 rs1058930 792C>G I264M 4.1  rs1058172 941G>A R314H 7.9
 rs11572103 805A>T I269F 16.4  rs59421388 859G>A V287M 5.3
2C9 rs28371686 1080C>G D360E 2.3  rs1065852 100C>T P34S 25.9
 rs28371685 1003C>T R335W 2.0 1A1 rs4646422 134GA G45D 6.7
 rs2256871 752A>G H251R 4.0  rs17861094 233T>C I78Thr 8.3
Data was extracted from the 1,000 Genomes Project site (http://www.1000genomes.org/) [23]. A more detailed table can be found in the supplemental material. Possibly
CYP-activity damaging SNPs are included in Table S2.
doi: 10.1371/journal.pone.0082562.t002
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The hyponatremia is the result of increased expression of
aquaporins 1 and 7, which is induced by CPA [65]. CYP 2B6
has high expression in kidneys, indicating that a higher level of
active CPA is likely to occur in the kidneys and lead to the
undesirable side effect.
Conclusions
In summary, the current study identified four major CYPs
(1A2, 2D6, 2C9 and 2C19) and 34 polymorphic alleles with a
significant impact on the drug metabolism in the Caucasian
population. Once genomic testing becomes part of routine
analysis, this data enables prediction of complications in drug
therapy and development of a personalized treatment regimen,
where drug dosages are based on an individual’s specific CYP
profile [6]. Ultimately, this approach may prevent treatment
failures and avoid unnecessary side effects. Another interesting
field could be the consideration of CYP polymorphisms in
clinical trials. Potentially, it would decrease the failures if
information of potential polymorphisms in different ethnic
groups was included. Findings from the current study will be
included in the SuperCYP database.
With the aim of assessing the effects of CYP polymorphisms
on chemotherapy and establishing a cost efficient method to
detect relevant CYP polymorphisms, a retrospective study in
leukemia cells from pediatric patients is currently under way
[66].
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